title: Natural killer and lymphokine-activated killer cell-mediated cytotoxicity in patients with oral cancer.
abstract: Peripheral blood lymphocytes (PBL) from untreated and treated oral cancer patients, lymph node lymphocytes (LNL) from metastatic (met) and nonmetastatic (non-met) lymph nodes, and tumor infiltrating lymphocytes (TIL) were tested for natural killer (NK) and lymphokine activated killer (LAK) cell cytotoxicity using appropriate targets in a short-term chromium release assay. The results showed that while both NK and LAK functions of PBL from oral cancer patients were comparable to those of normal healthy donors, the NK activity of metastatic and nonmetastatic LNL and TIL was highly compromised. On the other hand, potent LAK activity could be generated from all three lymphoid populations. Individual patients showing low NK activity displayed good LAK cytotoxicity, indicating that endogenous cells with low NK potential have adequate ability to respond to interleukin 2 (IL-2). LAK activity tested on autologous tumour targets revealed that TIL were the best source of LAK cells. followed by PBL and LNL.
authors.affiliation: Immunology Division, Cancer Research Institute, Tata Memorial Hospital, Bombay, India.
authors.forename: S G
authors.initials: SG
authors.lastname: Gangal
authors.forename: R J
authors.initials: RJ
authors.lastname: Tatake
authors.forename: N
authors.initials: N
authors.lastname: Krishnan
authors.forename: R
authors.initials: R
authors.lastname: Mukhopadhyaya
authors.forename: S L
authors.initials: SL
authors.lastname: Naik
authors.forename: A R
authors.initials: AR
authors.lastname: Fakih
authors.forename: R S
authors.initials: RS
authors.lastname: Rao
mesh_terms: D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D006801:Humans; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology*; D008198:Lymph Nodes / Q000276:immunology; D008545:Melanoma / Q000276:immunology; D009062:Mouth Neoplasms / Q000276:immunology* / Q000628:therapy; D009362:Neoplasm Metastasis / Q000276:immunology; D009364:Neoplasm Recurrence, Local / Q000276:immunology; D014407:Tumor Cells, Cultured / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000276:immunology